HC Wainwright Reiterates Buy on Eupraxia Pharmaceuticals With $11 Target
HC Wainwright & Co. reiterated their Buy rating on Eupraxia Pharmaceuticals's stock with a price target of $11.00. The price target implies a downside of 15.3% from the Sep 30 close of $12.99.